drugset / Trial / NCT04145297
Ulixertinib (BVD-523) and Hydroxychloroquine in Patients W Advanced MAPK-Mutated Gastrointestinal Adenocarcinomas
NaSingle-groupOpen-labelTreatment
Summary
Open-label dose escalation of Ulixertinib combined with fixed dose of hydroxychloroquine.
Timeline
- Start
- 2020-03-17
- Primary completion
- 2022-06-10
- Completion
- 2022-08-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Hydroxychloroquine | Small molecule | 600 mg | Oral |
| Subject | Ulixertinib | Small molecule | 300 mg | Oral |
| Subject | Ulixertinib | Small molecule | 450 mg | Oral |
| Subject | Ulixertinib | Small molecule | 600 mg | Oral |